Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from MapLight Therapeutics, Inc. ( (MPLT) ) is now available.
On January 9, 2026, MapLight Therapeutics announced it now expects topline Phase 2 results for its ZEPHYR and IRIS clinical trials—evaluating ML-007C-MA in schizophrenia and ML-004 in autism spectrum disorder—to be disclosed in the third quarter of 2026, a timing update that investors will monitor closely given the programs’ potential to address significant unmet needs in CNS disorders. The company also updated its corporate presentation for investor and analyst meetings, underscoring a broad CNS pipeline, projected milestones across schizophrenia, Alzheimer’s disease psychosis, autism spectrum disorder, Parkinson’s disease and other indications, and a strong capital position that may support continued clinical execution and reinforce its competitive positioning in the emerging muscarinic and circuit-targeted therapeutics space.
The most recent analyst rating on (MPLT) stock is a Hold with a $16.50 price target. To see the full list of analyst forecasts on MapLight Therapeutics, Inc. stock, see the MPLT Stock Forecast page.
Spark’s Take on MPLT Stock
According to Spark, TipRanks’ AI Analyst, MPLT is a Neutral.
The score is primarily weighed down by weak financial performance—no revenue, expanding losses, and rising cash burn—partly offset by a low-leverage balance sheet. Technicals are also soft with the price below its 20-day average and a subdued RSI, though oversold signals provide a modest counterbalance. Valuation is neutral due to missing P/E and dividend yield.
To see Spark’s full report on MPLT stock, click here.
More about MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on central nervous system disorders, leveraging a circuit-based discovery platform to develop novel therapies for conditions such as schizophrenia, Alzheimer’s disease psychosis, autism spectrum disorder, Parkinson’s disease, and hyperactivity/impulsivity. Its pipeline includes lead candidate ML-007C-MA, a potential best-in-class M1/M4 muscarinic agonist co-formulated with a peripheral antagonist, and ML-004, a 5-HT1B/1D agonist for autism spectrum disorder, supported by an estimated $450 million cash position and funding runway through 2027.
Average Trading Volume: 376,052
Current Market Cap: $728.7M
See more data about MPLT stock on TipRanks’ Stock Analysis page.